Clinical trials: Relapsed Cancer
Relapsed Solid Tumors, Refractory Solid Tumors
Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia.
- Conditions
- Relapsed Solid Tumors, Refractory Solid Tumors, Relapsed Leukemia, Refractory Leukemia
- Trial name
- POE14-01 (NCT02512926)
- Testing
- Carfilzomib, Cyclophosphamide, Etoposide
- Where
- 8 sites in United States, Canada
- Volunteers
- 4 people
- Sponsor
- Stanford University
Graft-versus-leukemia, Graft vs Host Disease
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
This study will provide follow-up evaluation and care of patients who have undergone allogeneic (donor) stem cell transplantation at the NIH Clinical Center.
- Conditions
- Graft-versus-leukemia, Graft vs Host Disease, Graft Rejection
- Trial name
- NCT00106925
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00253552
- Testing
- filgrastim, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- OHSU Knight Cancer Institute
Juvenile Myelomonocytic Leukemia, Neurofibromatosis Type 1
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment (refractory).
- Trial name
- NCT03190915
- Testing
- Bone Marrow Aspiration and Biopsy, Trametinib
- Where
- 57 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
This study involved patients that have a cancer called diffuse large B cell lymphoma (DLBCL), NK and T cell lymphomas (NK/TL) or classical Hodgkin lymphoma (cHL) (hereafter these 3 diseases will be referred to as lymphoma).
- Trial name
- NCT04288726
- Testing
- CD30.CAR-EBVST cells
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Baylor College of Medicine
Lymphoma
LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL)
Patients have a type of cancer called Hodgkin's lymphoma or non-Hodgkin's lymphoma, which has come back or not gone away or is at high risk for coming back after treatment, including the best treatment investigators know for this…
- Trial name
- ACDAL (NCT00082225)
- Testing
- CD45 antibodies, EBV specific T cells
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Baylor College of Medicine
B-cell Lymphoma Refractory
Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas
This is a single center, open label, phase 1 lead in to determine Recommended Phase 2 Dose (RP2D), followed by a phase 2 trial to evaluate the safety and efficacy of Epo-R-CD19 CAR T with or without CD22 CAR T-cells infused into…
- Trial name
- NCT07319676
- Testing
- CART infusion
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- National University Hospital, Singapore
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
This pilot study examines the safety and efficacy of anti-CD19 CAR T cells manufactured on-site in children and young adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin…
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Acute Lymphoblastic Leukemia With Failed Remission
- Trial name
- NCT05779930
- Testing
- CD19 specific Chimeric Antigen Receptor T Cell
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nationwide Children's Hospital
Glioma, Astrocytoma
Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)
The purpose of this study is to confirm the safety and efficacy of temozolomide in patients with newly diagnosed malignant glioma (concomitant with radiotherapy and then as monotherapy) and relapsed malignant glioma (as…
- Trial name
- NCT00705198
- Testing
- Temozolomide (for newly diagnosed malignant glioma), Temozolomide (for relapsed malignant glioma), Radiotherapy (for patients with newly diagnosed malignant glioma)
- Volunteers
- 1,804 people
- Sponsor
- Merck Sharp & Dohme LLC
Lymphoma
Combination Chemotherapy in Hodgkin's Disease or Non-Hodgkin's Lymphoma Not Responding to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00014209
- Testing
- cisplatin, dexamethasone, gemcitabine hydrochloride
- Where
- 13 sites in Canada
- Volunteers
- 77 people
- Sponsor
- NCIC Clinical Trials Group
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma
Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas
This study involved patients that have a cancer called diffuse large B cell lymphoma (DLBCL), NK and T cell lymphomas (NK/TL) or classical Hodgkin lymphoma (cHL) (hereafter these 3 diseases will be referred to as lymphoma).
- Trial name
- NCT04952584
- Testing
- CD30.CAR-EBVST cells
- Where
- 2 sites in United States
- Sponsor
- Baylor College of Medicine
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to < 18 years) with relapsing neuromyelitis optica spectrum disorder (NMOSD).
- Trial name
- NCT04155424
- Testing
- Eculizumab
- Where
- 35 sites in United States, Canada and 5 more
- Volunteers
- 5 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Leukemia, Lymphoblastic, Leukemia
Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL
To learn if the combination of 2 study drugs, CB-103 and venetoclax, can help to control T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic leukemia (T-LBL) in adolescent and young adult patients
- Trial name
- NCT05464836
- Testing
- CB-103, Venetoclax
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroblastoma
MIBG With Dinutuximab +/- Vorinostat
131I-Metaiodobenzylguanidine (131I-MIBG) is one of the most effective therapies utilized for neuroblastoma patients with refractory or relapsed disease.
- Trial name
- NCT03332667
- Testing
- 131I-MIBG, Dinutuximab, Vorinostat
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Sarcoma, Childhood Osteosarcoma
Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas
RAD3CAR is a phase I study designed to evaluatethe safety of B7-H3-CAR T cells and lymphodepletion in combination with hypofractionated radiation therapy.
- Conditions
- Sarcoma, Childhood Osteosarcoma, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma
- Trial name
- NCT07222735
- Testing
- Fludarabine, Cyclophosphamide, B7-H3-CAR T Cells
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- St. Jude Children's Research Hospital
Cancer, Chronic Lymphocytic Leukemia (CLL)
A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)
This study will collect real-world safety and efficacy data from Japanese relapse/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) participants treated with venetoclax.
- Conditions
- Cancer, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL)
- Trial name
- VENCLL regPMOS (NCT04198415)
- Where
- 102 sites in Japan
- Volunteers
- 4 people
- Sponsor
- AbbVie
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
This pilot phase II trial studies how well a new reduced intensity conditioning regimen that includes haploidentical donor NK cells followed by the infusion of selectively T-cell depleted progenitor cell grafts work in treating…
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT02259348
- Testing
- Cyclophosphamide, Fludarabine, G-CSF
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- St. Jude Children's Research Hospital
Acute T-Lymphocytic Leukemia
Venetoclax Based Regimen for R/R T-ALL
This study is to investigate the therapeutic efficacy and side effect of venetoclax based regimen for relapsed or refractroy T cell acute lymphoblastic leukemia.
- Trial name
- NCT05149378
- Testing
- Venetoclax combined with azacitidine regimen
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory
Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
This is a Phase I clinical study evaluating the safety and maximum tolerated dose of a novel CAR T-cell product: allogeneic memory (CD45RA- negative) T-cells expressing a CD19-specific CAR 41BBz (CD19-CAR.CD45RA- negative…
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL
- Trial name
- NCT04881240
- Testing
- CD19-CAR(Mem) T-cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Myeloid Leukemia, Genetic Predisposition to Disease
Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies
Pediatric acute myeloid leukemias are disease with poor prognosis (overall survival of 60-75%) and high relapse rate of 35-45% require further understanding of the underlying biological mechanisms.
- Trial name
- ALARM3 (NCT05772559)
- Testing
- Collection of blood sample of bone marrow (cohort 1), Collection of blood sample of bone marrow (cohort 2 and 3)
- Where
- 28 sites in France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.